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The influence of metoclopramide 
on pharmacokinetics and 
pharmacodynamics of ticagrelor 
in patients with unstable angina 
pectoris receiving concomitant 
treatment with morphine — a protocol  
of a randomized trial
ABSTRACT
Introduction. Nowadays, due to the “morphine effect”, the screening of methods that provide quick 
and effective platelet inhibition with oral P2Y12 inhibitors administrated simultaneously with morphine 
in patients with acute coronary syndromes are extensively investigated by numerous scientists. Meto-
clopramide, which stimulates the motility of gastrointestinal tract, may become a potential method of 
overcoming the negative morphine effect. The present study was designed to demonstrate the influence 
of metoclopramide administration on the pharmacokinetic and pharmacodynamic profile of ticagrelor 
between patients with unstable angina pectoris treated with morphine and crushed ticagrelor. 
Methods/design. A study was designed as a phase IV, single-centre, randomized, investigator-initiated, 
parallel-group, open-label, interventional trial. Patients will be randomized in a 1:1 manner into two arms: 
1) patients treated with a combination of crushed ticagrelor and morphine and 2) patients treated with 
a combination of crushed ticagrelor followed by morphine and metoclopramide. Blood sample collection 
will be scheduled directly before the administration of ticagrelor loading dose and 15, 30, 45, 60, 120, 
180, 240, and 360 minutes after the loading dose. Pharmacokinetic and pharmacodynamic assessment 
of ticagrelor and its active metabolite will be evaluated in all pre-defined time points.
Discussion. The current study is, to our knowledge, the first one to provide data on the influence of metoclo-
pramide in patients with acute coronary syndromes, who received intravenous opioid analgesia. It is expected 
to contribute to the development of contemporary knowledge on the treatment of patients presenting with 
acute coronary syndromes, and should enable clinicians to implement strategies of quick platelet inhibition.
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Introduction
Platelets play a key role in acute coronary syn-
dromes (ACS). After atherosclerotic plaque rupture, 
platelets could form pathogenic, occlusive thrombi, 
which leads to acute ischaemic events [1]. Current 
antiplatelet pharmacological therapy relies on admin-
istration of aspirin to patients, as well as oral P2Y12 in-
hibitors. However, according to numerous clinical trials 
in patients with ACS, the administration of prasugrel or 
ticagrelor is preferred, compared to clopidogrel [2–5].
In order to relieve pain and anxiety, morphine is 
a commonly used drug in the acute phase of ACS [6, 7]. 
Nevertheless, in patients with ST segment elevation 
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myocardial infarction (STEMI), in which the effective 
platelet inhibition is required, the delayed onset of 
platelet inhibition was demonstrated, especially in 
patients treated with morphine [8–10]. 
Nowadays, due to the “morphine effect”, the screen-
ing of methods that provide quick and effective platelet 
inhibition with oral P2Y12 inhibitors administrated simul-
taneously with morphine in ACS patients are extensively 
investigated by numerous scientists. Previously report-
ed studies showed that the administration of crushed 
ticagrelor increased both ticagrelor and its active 
metabolite concentration in human plasma [11, 12]. 
Additionally, in patients treated with crushed ticagrelor, 
earlier inhibition of platelet aggregation was observed, 
compared to the reports in which the integral tablets 
were given [13, 14]. Venetsanos et al. also confirmed 
that the administration of chewed tablets is feasible 
and provides faster inhibition than the administration 
of either crushed or integral tablets [15]. 
Metoclopramide, as a well-known and commonly 
used prokinetic drug which stimulates the motility of 
gastrointestinal tract, may become a potential method of 
overcoming the negative morphine effect. The present 
study was designed to demonstrate the influence of 
metoclopramide administration on the pharmacokinetic 
and pharmacodynamic profile of ticagrelor between 
patients with unstable angina pectoris treated with 
morphine and crushed ticagrelor. 
Methods
The study was designed as a phase IV, single-cen-
tre, randomized, investigator-initiated, parallel-group, 
open-label, interventional trial. We plan to evaluate 
differences in the pharmacokinetic and pharmaco-
dynamic profile of ticagrelor and it active metabolite 
AR-C1249XX between patients hospitalised for unstable 
angina pectoris, who received either a combination of 
crushed ticagrelor and morphine or crushed ticagrelor, 
morphine, and metoclopramide. The study protocol was 
approved by the Ethics Committee of Nicolaus Coper-
nicus University in Toruń, Ludwik Rydygier Collegium 
Medicum in Bydgoszcz and received approval number 
KB 339/2016. Provision of informed consent will be 
needed for each patient to enrol in the study. 
Eligibility screening will be based on inclusion 
criteria including, clinical diagnosis of unstable angina 
pectoris, low-intermediate mortality risk (< 140 pts) 
assessed with GRACE score, males and non-pregnant 
females 18–80 years old, informed consent for coronary 
angiography, and percutaneous coronary intervention if 
required. Major exclusion criteria comprise concomitant 
treatment with any P2Y12 receptor inhibitor (or treat-
ment terminated within 14 days preceding the screen-
ing), treatment with any opioid “mi” receptor agonist, 
current use of oral anticoagulants or chronic therapy 
with low-molecular-weight heparin, active bleeding, 
history of intracranial haemorrhage, bradycardia, and 
second- or third-degree atrioventricular block during 
screening for eligibility. The complete list of inclusion 
and exclusion criteria used in the study is presented 
in Table 1. 
The study will be performed in the Department of 
Cardiology, Antoni Jurasz University Hospital No. 1 in 
Bydgoszcz, Poland. All participants, after providing 
informed consent, will be randomized in a 1:1 manner 
into two arms:
Table 1. Complete list of inclusion/exclusion criteria in 
the study
Inclusion criteria
Provision of informed consent prior to any study-specific 
procedures
Diagnosis of unstable angina
Male or non-pregnant female, aged 18–80 years 
Provision of informed consent for angiography and PCI
GRACE score < 140 pts
Exclusion criteria
Treatment with ticlopidine, clopidogrel, prasugrel, or ticagrelor 
within 14 days before the study enrolment
Current treatment with morphine or any opioid “mi” receptor 
agonist 
Hypersensitivity to ticagrelor
Current treatment with oral anticoagulant or chronic therapy 
with low-molecular-weight heparin
Active bleeding
History of intracranial haemorrhage
Recent gastrointestinal bleeding (within 30 days)
History of coagulation disorders
Platelet count less than < 100 × 103/µL
Haemoglobin concentration less than 10.0 g/dL
History of moderate or severe hepatic impairment
History of major surgery or severe trauma (within 3 months)
Risk of bradycardic events as judged by the investigator
Second- or third-degree atrioventricular block during 
screening for eligibility
History of asthma or severe chronic obstructive pulmonary disease
Kidney disease requiring dialysis
Manifest infection or inflammatory state
Killip class III or IV during screening for eligibility
Respiratory failure
History of severe chronic heart failure (NYHA class III or IV)
Concomitant therapy with strong CYP3A inhibitors 
(ketoconazole, itraconazole, voriconazole, telithromycin, 
clarithromycin, nefazadone, ritonavir, saquinavir, nelfinavir, 
indinavir, atazanavir) or strong CYP3A inducers (rifampicin, 
phenytoin, carbamazepine, dexamethasone, phenobarbital) 
within 14 days and during study treatment
Body weight below 50 kg
PCI — percutaneous coronary interventions
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 — patients treated with a combination of crushed 
ticagrelor and morphine (5 mg administered intra-
venously) and 
 — patients treated with a combination of crushed ti-
cagrelor followed by morphine (5 mg administered 
intravenously) and metoclopramide (10 mg admin-
istered intravenously). 
After the randomization, blood sample collection 
(time point 0) is planned. Immediately after, a ticagrelor 
loading dose (LD) will be administered. The schematic 
diagram of the study is presented in Figure 1.
Endpoints
The time for ticagrelor and its active metabolite AR-
C124900XX to reach maximum plasma concentration 
within time frame of six hours after administration of 
ticagrelor LD (tmax) was determined as the primary 
outcome of the study. 
The study secondary outcomes comprise ticagrelor 
and AR-C124900XX maximum plasma concentration, 
area under the plasma concentration-time curve for 
ticagrelor and AR-C124900XX (AUC 0–6 hours), and 
platelet reactivity assessed with Multiple Electrode Ag-
gregometry (MEA) measured with a Multiplate Analyzer 
directly before ticagrelor LD and within a time frame of 
six hours following ticagrelor LD. The complete list of 
the study outcomes is presented in Table 2.
Figure 1. Diagram presenting patient’s flow through the study; LD — loading dose
Table 2. List of study endpoints
Primary endpoint of the study
Time to maximum concentration (tmax) for ticagrelor and AR-C124900XX (time frame: 6 h)
Secondary endpoints of the study
Maximum ticagrelor and AR-C124900XX concentration (time frame: 6 h)
Area under the plasma concentration-time curve for ticagrelor (AUC 0–6 h) (time frame: pre-dose and 15 min, 30 min, and 45 
min, and 1, 2, 3, 4, and 6 h post dose)
Area under the plasma concentration-time curve for AR-C124900XX (AUC 0–6 h) (time frame: pre-dose and 15 min, 30 min, and 
45 min, and 1, 2, 3, 4, and 6 hours post dose)
Platelet reactivity assessed by Multiple Electrode Aggregometry (time frame: pre-dose and 30 min, and 1, 2, 3, 4, and 6 hours 
post dose)
Pharmacokinetics and pharmacodynamics
Pharmacokinetic and pharmacodynamic properties 
of ticagrelor and its active metabolite will be evaluated 
for all patients enrolled in the study. Pharmacokinetic 
assessment will be performed by the workers of the De-
partment of Medicinal Chemistry, Nicolaus Copernicus 
University, Ludwik Rydygier Collegium Medicum in Byd-
goszcz using the Shimadzu UPLC Nexera X2 system 
consisting of LC-30AD pumps, SIL-30AC Autosampler, 
CTO-20AC column oven, FCV-20-AH2 valve unit, 
and DGU-20A5R degasser coupled with a Shimadzu 
8030 ESI-triple quadrupole mass spectrometer.
Platelet activity will be investigated by blinded re-
searchers in the internal laboratory of the Department 
of Cardiology using Multiple Electrode Aggregometry 
(MEA; the Multiplate Analyzer, Roche Diagnostics 
International Ltd, Rotkreuz, Switzerland). The meth-
ods of both pharmacokinetic and pharmacodynamic 
assessment have been described previously [10, 16].
Blood sample collection
Blood sample collection will be scheduled directly 
before the administration of ticagrelor LD and 15, 30, 
45, 60, 120, 180, 240, and 360 minutes after the LD. 
The process of blood collection will be performed by 
the Cardiology Department nurses and supervised by 
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a physician responsible for each patient’s recruitment. 
An intravenous catheter will be used to reduce the pa-
tient’s inconvenience associated with blood collection. 
Safety of the trial
Only patients diagnosed with unstable angina pec-
toris scoring less than 140 points in GRACE score (low 
or intermediate mortality risk) will be enrolled in the 
study. All participants will be administered standard 
medications recommended by the ESC guidelines for 
ACS management, which include 300 mg aspirin loading 
dose, statins, beta-blockers, angiotensin converting en-
zyme inhibitors, or angiotensin II receptor inhibitors. The 
patient’s participation in the study will be immediately ter-
minated in the case of any medical conditions requiring 
urgent coronary angiography. All study participants will 
be administered ticagrelor maintenance dose of 90 mg 
twice daily throughout the hospitalisation. Treatment 
with ticagrelor after discharge will be recommended 
to each patient at the end of the hospitalisation period. 
However, a switch to clopidogrel for patients unable 
to continue therapy with ticagrelor (especially due to 
economic reasons) will be possible before discharge. 
These patients will receive a clopidogrel LD of 600 mg. 
A single low dose of morphine will be adminis-
tered intravenously directly after provision of informed 
consent by each study participant. In the case of any 
adverse events that may be associated with the use 
of morphine, an opioid antagonist, naloxone, will be 
administered to reverse all morphine effects.
Discussion
The current study is, to our knowledge, the first one 
to provide data on the influence of metoclopramide 
in patients with ACS, who have received intravenous 
opioid analgesia. It is expected to contribute to the de-
velopment of contemporary knowledge on the treatment 
of patients presenting with ACS, and should enable clini-
cians to implement strategies of quick platelet inhibition.
The study status
The study was registered in clinicaltrials.gov with 
the identifier NCT02939235 and it is currently recruit-
ing participants.
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